Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eagle Hit With Double Whammy On Vasopressin ANDA Product

ANDA Filer Eagle Has Previously Suggested Launching ‘At Risk’

Executive Summary

Eagle Pharmaceuticals was gearing up for patent-litigation proceedings with Endo over Vasostrict on 1 February but has quickly seen the landscape shift.

You may also be interested in...

Eagle Swats More Vasopressin Hurdles As Petition And Injunction Are Denied

In a clean sweep for Eagle Pharmaceuticals, following its recent approval for the first generic version of Par’s Vasostrict, the ANDA sponsor has seen defeated a Par citizen petition and dodged injunctive action launched by the Endo subsidiary.

Eagle Soars As It Looks To 13-Year Head Start On Vasopressin In US

Following the disappointment of a complete response letter and delayed trial proceedings, Eagle has secured FDA approval for the first generic version of Par’s Vasostrict, which is tipped to have branded sales approaching $1bn in the US in 2021.

Eagle Victory Clears Way For US Vasopressin Launch

Eagle Pharmaceuticals has celebrated a US court ruling that clears the way for it to launch its generic vasopressin rival to Endo’s Vasostrict. However, the company is still waiting for FDA approval after its application was delayed by a CRL earlier this year, with a new action date provided by the agency.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts